SCHEMBL383949

SCHEMBL383949

CCCCCCCCCCCCCCCCCCOc1ccc(C2c3ccccc3Oc3ccccc32)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNA3 P22001 1/20 0.52
LTA4H P09960 2/20 0.49
NR5A1 Q13285 1/20 0.46
LMNA P02545 3/20 0.43
TP53 P04637 2/20 0.43
MAPT P10636 2/20 0.43
NPC1 O15118 1/20 0.43
GAA P10253 1/20 0.43
ALOX15 P16050 1/20 0.43
RAB9A P51151 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TSHR P16473 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
PLA2G4B P0C869 1/20 0.41
GPR174 Q9BXC1 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3261989 0.88 LMNA (0.46) KCNA3LTA4HNR5A1LMNATP53
SCHEMBL28233468 0.84 LTA4H (0.53) LTA4HNR5A1LMNATP53MAPT
SCHEMBL7999239 0.84 MAPT (0.53) KCNA3LTA4HLMNATP53MAPT
SCHEMBL13172506 0.84 TSHR (0.50) KCNA3LTA4HNR5A1TP53TSHR
SCHEMBL28184586 0.80 SPHK1 (0.48) LMNATP53MAPTHSD17B10TSHR
SCHEMBL8755176 0.80 LTA4H (0.48) LTA4HNR5A1LMNATP53NPC1
SCHEMBL13019592 0.79 TSHR (0.45) LTA4HGAATSHRPLA2G4B
SCHEMBL26778722 0.77 MAOA (0.49) KCNA3LTA4HNR5A1TSHRMEN1
SCHEMBL11689210 0.76 NR5A1 (0.58) LTA4HNR5A1LMNATP53MAPT
SCHEMBL707761 0.76 MAPT (0.53) LMNATP53MAPTNPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029513-A1 Methods And Compositions For Generating Mixtures Of Nucleic Acid Molecules AGILENT TECHNOLOGIES, INC. 2010-02-04 US claimed
EP-2121719-A2 2-5A DERIVATIVES AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI-PARASITIC AGENTS Alios Biopharma, Inc. (US) 2009-11-25 EP claimed
US-7576119-B2 Supports for oligomer synthesis ISIS PHARMACEUTICALS, INC. (US) 2009-08-18 US claimed
WO-2009086192-A1 BIODEGRADABLE PHOSPHATE PROTECTED NUCLEOTIDE DERIVATIVES AND THEIR USE AS CANCER, ANTI VIRAL AND ANTI PARASITIC AGENTS ALIOS BIOPHARMA, INC. (US) 2009-07-09 WO claimed
WO-2009086201-A1 2-5A ANALOGS AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI- PARAS ITI C AGENTS ALIOS BIOPHARMA, INC. (US) 2009-07-09 WO claimed
WO-2008095040-A2 2-5A DERIVATIVES AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI-PARASITIC AGENTS ALIOS BIOPHARMA, INC. (US) 2008-08-07 WO claimed
US-20080021224-A1 SUPPORTS FOR OLIGOMER SYNTHESIS ISIS PHARMACEUTICALS, INC. (US) 2008-01-24 US claimed
US-7202264-B2 Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides ISIS PHARMACEUTICALS, INC. (US) 2007-04-10 US claimed
EP-1670810-A2 GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLI CSUGAR MOIETIES AT THE TERMINI Isis Pharmaceuticals, Inc. (US) 2006-06-21 EP claimed
US-20050208588-A1 Supports for oligomer synthesis ISIS PHARMACEUTICALS, INC. (US) 2005-09-22 US claimed
WO-2000004062-A1 RECOVERY OF TRIARYLMETHYL HALIDE PROTECTING GROUPS CLEAVED DURING OLIGONUCLEOTIDE SYNTHESIS ISIS PHARMACEUTICALS, INC. (US) 2000-01-27 WO claimed
JP-H09510206-A 1997-10-14 JP claimed
US-5623068-A Synthesis of DNA using substituted phenylacetyl-protected nucleotides BECKMAN INSTRUMENTS, INC. (US) 1997-04-22 US claimed
EP-0749436-A1 COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES BECKMAN INSTRUMENTS, INC. (US) 1996-12-27 EP claimed
US-5574146-A Oligonucleotide synthesis with substituted aryl carboxylic acids as activators BECKMAN INSTRUMENTS, INC. (US) 1996-11-12 US claimed
EP-0725787-A1 ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF BECKMAN INSTRUMENTS, INC. (US) 1996-08-14 EP claimed
WO-1996006853-A1 ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF BECKMAN INSTRUMENTS, INC. (US) 1996-03-07 WO claimed
WO-1995024413-A1 COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES BECKMAN INSTRUMENTS, INC. (US) 1995-09-14 WO claimed
EP-0648220-A1 DEUTERATED NUCLEOSIDES CHATTOPADHYAYA, Jyoti (SE) 1995-04-19 EP claimed
WO-1993025566-A1 DEUTERATED NUCLEOSIDES CHATTOPADHYAYA JYOTI (SE) 1993-12-23 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021224-A1 SUPPORTS FOR OLIGOMER SYNTHESIS ILK, NOP2, PFAS KCNA3 3637/4885LTA4H 2418/4885NR5A1 4830/4885
US-20100029513-A1 Methods And Compositions For Generating Mixtures Of Nucleic Acid Molecules POLM, RNGTT, POLN KCNA3 4765/4885LTA4H 4384/4885NR5A1 4462/4885
US-20050208588-A1 Supports for oligomer synthesis ILK, NOP2, PFAS KCNA3 3637/4885LTA4H 2418/4885NR5A1 4830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.